Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Disrupting GRINL1A Association with Cereblon Accelerates IKZF1/3 Degradation and IMiD Killing of Mantle Cell Lymphoma Cells By CDK4/6 Inhibition

Nicole Zhao, Maurizio Di Liberto, PhD, Olivier Elemento, PhD, Selina Chen-Kiang, PhD, Xiangao Huang, PhD

Blood (2019) 134 (Supplement_1): 299.

https://doi.org/10.1182/blood-2019-128927

Published: 2019

Journal Articles

T-Cell Clonal Expansion and Activation Associated with Durable Clinical Response to Dual BTK and CDK4/6 Inhibitor Therapy in Mantle Cell Lymphoma

Christina Y. Lee, MD, Maurizio Di Liberto, PhD, Yang Hu, PhD, Xiangao Huang, PhD, Nancy L Bartlett, MD, Kami J. Maddocks, MD, John P. Leonard, MD, Nils-Petter Rudqvist, PhD, Lorenzo Galluzzi, PhD, Peter Martin, FRCPC, MD MS, Olivier Elemento, PhD, Selina Chen-Kiang, PhD

Blood (2019) 134 (Supplement_1): 3973.

https://doi.org/10.1182/blood-2019-122322

Published: 2019

Journal Articles

Composite Copy Number Variation in CDK4 , CDKN2A and RB1 Predisposes Mantle Cell Lymphoma to Expansion of PD1+ Tumor Cells and Resistance to CDK4/6 Inhibitor Therapy as Revealed by Integrative Longitudinal scRNA-seq

Maurizio Di Liberto, PhD, Yang Hu, PhD, Xiangao Huang, PhD, Christina Y. Lee, MD, Kevin Wang, B.S., Nancy L. Bartlett, MD, LeAnn Ridling, Kristie A. Blum, MD, Kami J. Maddocks, MD, Steven I Park, MD, Jia Ruan, MD PhD, Kenneth Eng, B.S., Lorenzo Galluzzi, PhD, John P. Leonard, MD, Peter Martin, FRCPC, MD MS, Olivier Elemento, PhD, Selina Chen-Kiang, PhD

Blood (2019) 134 (Supplement_1): 1492.

https://doi.org/10.1182/blood-2019-130944

Published: 2019

Journal Articles

Cooperative Repression of IRF4 and Induction of IRF7 By CDK4/6 Inhibition Sensitizes Mantle Cell Lymphoma Cells to IMiD-Mediated Apoptosis Independent of p16 Deletion or c-Myc Overexpression

Basel A Humos, Maurizio Di Liberto, PhD, Xiangao Huang, PhD, Olivier Elemento, PhD, Selina Chen-Kiang, PhD

Blood (2018) 132 (Supplement 1): 2864.

https://doi.org/10.1182/blood-2018-99-117487

Published: 2018

Journal Articles

PIK3IP1 Inhibition of PI3K in G1 Arrest Induced By CDK4 Inhibition Reprograms MCL for Ibrutinib Therapy

Maurizio Di Liberto, PhD, Xiangao Huang, PhD, Olivier Elemento, PhD, Ken Eng, Kristie A. Blum, MD, Nancy L. Bartlett, MD, Steven I. Park, MD, Jia Ruan, MD PhD, Kami J. Maddocks, MD, Giorgio Inghirami, MD, Lewis Cantley, MD, John P. Leonard, MD, Peter Martin, MD, Selina Chen-Kiang, PhD

Blood (2016) 128 (22): 610.

https://doi.org/10.1182/blood.V128.22.610.610

Published: 2016

Journal Articles

Cooperative Supression of MEIS2 Mediates Dexamethasone Enhancement of Lenalidomide Killing in Myeloma Cells

Sonia Allouch, David S Jayabalan, BSMS., MSc, Adriana C Rossi, MD, MSc, Ruben Niesvizky, MD, Xiangao Huang, PhD, Selina Chen-Kiang, PhD

Blood (2016) 128 (22): 3292.

https://doi.org/10.1182/blood.V128.22.3292.3292

Published: 2016

Journal Articles

A Phase I Trial of Ibrutinib Plus Palbociclib in Patients with Previously Treated Mantle Cell Lymphoma

Peter Martin, MD, Kristie Blum, MD, Nancy L. Bartlett, MD, Steven I. Park, MD, Kami J. Maddocks, MD, Jia Ruan, MD PhD, Maurizio Di Liberto, PhD, Xiangao Huang, PhD, Giorgio Inghirami, MD, Pamela Harris, MD, Selina Chen-Kiang, PhD, John P. Leonard, MD

Blood (2016) 128 (22): 150.

https://doi.org/10.1182/blood.V128.22.150.150

Published: 2016

Journal Articles

Inhibition of CDK4/CDK6 Sensitizes Myeloma to IMiD By Reducing the MEIS2 to Cereblon Ratio That Accelerates IKZF1 and IKZF3 Degradation

Xiangao Huang, PhD, David Jayabalan, BSMS, MSc, Maurizio Di Liberto, PhD, Zhengming Chen, PhD, Anna C Schinzel, PhD, Scott Ely, MD MPH, Adriana C Rossi, MD MHS, Roger N Pearse, MD PhD, Ekta Aneja, MBBS, Morton Coleman, MD, Joseph M Lane, MD, William C. Hahn, MD PhD, Tomer M Mark, MD MSc, Ruben Niesvizky, MD, Selina Chen-Kiang, PhD

Blood (2015) 126 (23): 500.

https://doi.org/10.1182/blood.V126.23.500.500

Published: 2015

Journal Articles

High-Dose Carfilzomib and Dexamethasone As First-Line Treatment in Symptomatic Multiple Myeloma

Tomer M Mark, MD MSc, Sujitha Yadlapati, MBBS, Lyubov Neglyad, Jennifer Bourke, RN, David Jayabalan, BSMS, MSc, Adriana C Rossi, MD, Roger N Pearse, MD PhD, Arthur Perry, PA, Karen Pekle, NP, Kathleen Pogonowski, RN, Linda Tegnestam, RN, Xiangao Huang, PhD, Maurizio Di Liberto, PhD, Scott Ely, MD MPH, Morton Coleman, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2015) 126 (23): 4258.

https://doi.org/10.1182/blood.V126.23.4258.4258

Published: 2015

Journal Articles

Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Overcomes Negative Prognostic Impact of Adverse Cytogenetics and Prior Resistance to Lenalidomide and Bortezomib

Tomer M Mark, MD MSc, Angelique Boyer, Sujitha Yadlapati, MBBS, Adriana C Rossi, MD, Roger N Pearse, MD PhD, Karen Pekle, NP, Arthur Perry, PA, Kathleen Pogonowski, RN, Ekta Aneja, MD, Linda Tegnestam, RN, David Jayabalan, BSMS, MSc, Scott Ely, MD MPH, Morton Coleman, MD, Xiangao Huang, PhD, Maurizio Di Liberto, PhD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2015) 126 (23): 4232.

https://doi.org/10.1182/blood.V126.23.4232.4232

Published: 2015

Journal Articles

Sensitizing shRNA Screen for Molecular Targets in CDK4/CDK6-Based Combination Therapy in Multiple Myeloma

Xiangao Huang, PhD, Maurizio Di Liberto, PhD, David Chiron, PhD, Ruben Niesvizky, MD, Anna C. Schinzel, PhD, William C. Hahn, MD PhD, Selina Chen-Kiang, PhD

Blood (2014) 124 (21): 3440.

https://doi.org/10.1182/blood.V124.21.3440.3440

Published: 2014

Journal Articles

The Combination Of Palbociclib Plus Bortezomib Is Safe and Active In Patients With Previously Treated Mantle Cell Lymphoma: Final Results Of a Phase I Trial

Peter Martin, MD, Maurizio DiLiberto, PhD, Christopher E Mason, PhD, Scott A Ely, M.D., Jia Ruan, MD, PhD, Richard R. Furman, MD, David Chiron, PhD, Xiangao Huang, PhD, David C Madoff, M.D., Jonathan Navi, Jessica Lewis, PA-C, Alison Bender, PA-C, Amelyn Rodriguez, RN, June Greenberg, RN, Morton Coleman, MD, Selina Chen-Kiang, PhD, John P. Leonard, M.D.

Blood (2013) 122 (21): 4393.

https://doi.org/10.1182/blood.V122.21.4393.4393

Published: 2013

Journal Articles

Integrative Whole Transcriptome and Exome Sequencing Reveals Reprogramming Of Mantle Cell Lymphoma In Prolonged Early G1 Arrest For Clinical Response To Selective Inhibition Of CDK4 In Combination Therapy

David Chiron, PhD, Peter Martin, MD, Maurizio Di Liberto, Ph.D., Xiangao Huang, PhD, Priyanka Vijay, B.A, Pedro Blecua, PhD, Scott A Ely, MD, MPH, Olivier Elemento, PhD, Christopher E Mason, PhD, John P. Leonard, MD, Selina Chen-Kiang, PhD

Blood (2013) 122 (21): 80.

https://doi.org/10.1182/blood.V122.21.80.80

Published: 2013

Journal Articles

Synergistic Loss of IRF4 and Induction of IRF7 Sensitizes Primary Myeloma Cells to IMiD Killing by IFNβ in Prolonged Early G1 Arrest Induced by CDK4/CDK6 Inhibition

Xiangao Huang, PhD, David Jayabalan, B.S.M.S, Maurizio Di Liberto, Ph.D., Jackson D Harvey, B.S., Anna C. Schinzel, PhD, Tomer M Mark, MD, MSc, Mohamad Hussein, MD, Sophia Randolph, MD, PhD, William C. Hahn, MD, PhD, Ruben Niesvizky, MD, Selina Chen-Kiang, PhD

Blood (2012) 120 (21): 572.

https://doi.org/10.1182/blood.V120.21.572.572

Published: 2012

Journal Articles

Induction of Early G1-Arrest by CDK4/CDK6 Inhibition Sensitizes Mantle Cell Lymphoma Cells to Selective PI3Kδ Inhibition by GS-1101 Through Enhancing the Magnitude and Duration of p-AKT Inhibition

David Chiron, PhD, Peter Martin, MD, Maurizio Di Liberto, Ph.D., Xiangao Huang, PhD, Scott A Ely, MD, MPH, Brian J. Lannutti, PhD, John P. Leonard, MD, Christopher E. Mason, PhD, Selina Chen-Kiang, PhD

Blood (2012) 120 (21): 791.

https://doi.org/10.1182/blood.V120.21.791.791

Published: 2012

Journal Articles

Mutation Burden in CDKN2C, CDK1 and E2F2 Is Associated with Differential Response to Targeting CDK4/CDK6 in Combination with Bortezomib in Mantle Cell Lymphoma,

Christopher E. Mason, PhD, Maurizio Di Liberto, Ph.D., Xiangao Huang, PhD, David Chiron, PhD, Jamieson Bretz, Ph.D., Ramsey Abdallah, B.S., Scott A Ely, M.D., Daniel M Knowles, MD, Peter Martin, MD, John P. Leonard, MD, Selina Chen-Kiang, PhD

Blood (2011) 118 (21): 3738.

https://doi.org/10.1182/blood.V118.21.3738.3738

Published: 2011

Journal Articles

Bim Is Required to Sensitize Mantle Cell Lymphoma Cells for Killing by Bortezomib, but Not Ara-C, by Selective Inhibition of CDK4/CDK6

Xiangao Huang, PhD, Maurizio Di Liberto, Ph.D., Jamieson Bretz, Ph.D., David Chiron, PhD, Peter Martin, MD, Morton Coleman, MD, Jia Ruan, MD, PhD, Mitchell R Smith, MD, PhD, Scott A Ely, M.D., Christopher E. Mason, PhD, Phoebe Joy Ho, MBBS, DPhil, John P. Leonard, MD, Selina Chen-Kiang, PhD

Blood (2011) 118 (21): 1655.

https://doi.org/10.1182/blood.V118.21.1655.1655

Published: 2011

Journal Articles

A Phase I Study of PD 0332991: Complete CDK4/6 Inhibition and Tumor Response In Sequential Combination with Bortezomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma

Ruben Niesvizky, MD, Suzanne Lentzsch, MD, PhD, Ashraf Z. Badros, MD, Asher A. Chanan-Khan, MD, Seema B. Singhal, MD, Jeffrey A. Zonder, MD, Ravi Vij, MBBS, MD, Xiangao Huang, PhD, Maurizio DiLiberto, PhD, Rachel Courtney, PhD, M. Naveed Shaik, PhD, Sindy T. Kim, BS, Sophia Randolph, MD, PhD, Scott A Ely, MD, MPH, Selina Chen-Kiang, PhD

Blood (2010) 116 (21): 860.

https://doi.org/10.1182/blood.V116.21.860.860

Published: 2010

Journal Articles

MAGE-A Inhibits Apoptosis In Proliferating Multiple Myeloma Cells

Tricia Nardiello, BA, Achim A Jungbluth, MD, Anna Mei, BA, Maurizio DiLiberto, PhD, Xiangao Huang, PhD, Scott A Ely, MD, MPH, Ruben Niesvizky, MD, Morton Coleman, MD, Roger N Pearse, MD, PhD, David Jayabalan, B.S.M.S, Lloyd J Old, MD, Selina Chen-Kiang, PhD, Hearn J. Cho, MD, PhD

Blood (2010) 116 (21): 785.

https://doi.org/10.1182/blood.V116.21.785.785

Published: 2010

Journal Articles

A Phase I Trial of PD 0332991, a Novel, Orally-Bioavailable CDK4/6-Specific Inhibitor Administered in Combination with Bortezomib and Dexamethasone to Patients with Relapsed and Refractory Multiple Myeloma.

Ruben Niesvizky, MD, Scott Ely, MD, MPH, David S Jayabalan, Megan C. Manco, Seema Singhal, MD, Mary Crann, Rachel Courtney, Cynthia DuFresne, Keith D. Wilner, PhD, Isan Chen, MD, Tomer Mark, MD, John P. Leonard, MD, Morton Coleman, MD, Maurizio DiLiberto, PhD, Xiangao Huang, PhD, Selina Chen-Kiang, PhD

Blood (2009) 114 (22): 1877.

https://doi.org/10.1182/blood.V114.22.1877.1877

Published: 2009

NARROW

Disrupting GRINL1A Association with Cereblon Accelerates IKZF1/3 Degradation and IMiD Killing of Mantle Cell Lymphoma Cells By CDK4/6 Inhibition

T-Cell Clonal Expansion and Activation Associated with Durable Clinical Response to Dual BTK and CDK4/6 Inhibitor Therapy in Mantle Cell Lymphoma

Composite Copy Number Variation in CDK4 , CDKN2A and RB1 Predisposes Mantle Cell Lymphoma to Expansion of PD1+ Tumor Cells and Resistance to CDK4/6 Inhibitor Therapy as Revealed by Integrative Longitudinal scRNA-seq

Cooperative Repression of IRF4 and Induction of IRF7 By CDK4/6 Inhibition Sensitizes Mantle Cell Lymphoma Cells to IMiD-Mediated Apoptosis Independent of p16 Deletion or c-Myc Overexpression

PIK3IP1 Inhibition of PI3K in G1 Arrest Induced By CDK4 Inhibition Reprograms MCL for Ibrutinib Therapy

Cooperative Supression of MEIS2 Mediates Dexamethasone Enhancement of Lenalidomide Killing in Myeloma Cells

A Phase I Trial of Ibrutinib Plus Palbociclib in Patients with Previously Treated Mantle Cell Lymphoma

Inhibition of CDK4/CDK6 Sensitizes Myeloma to IMiD By Reducing the MEIS2 to Cereblon Ratio That Accelerates IKZF1 and IKZF3 Degradation

High-Dose Carfilzomib and Dexamethasone As First-Line Treatment in Symptomatic Multiple Myeloma

Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Overcomes Negative Prognostic Impact of Adverse Cytogenetics and Prior Resistance to Lenalidomide and Bortezomib

Sensitizing shRNA Screen for Molecular Targets in CDK4/CDK6-Based Combination Therapy in Multiple Myeloma

The Combination Of Palbociclib Plus Bortezomib Is Safe and Active In Patients With Previously Treated Mantle Cell Lymphoma: Final Results Of a Phase I Trial

Integrative Whole Transcriptome and Exome Sequencing Reveals Reprogramming Of Mantle Cell Lymphoma In Prolonged Early G1 Arrest For Clinical Response To Selective Inhibition Of CDK4 In Combination Therapy

Synergistic Loss of IRF4 and Induction of IRF7 Sensitizes Primary Myeloma Cells to IMiD Killing by IFNβ in Prolonged Early G1 Arrest Induced by CDK4/CDK6 Inhibition

Induction of Early G1-Arrest by CDK4/CDK6 Inhibition Sensitizes Mantle Cell Lymphoma Cells to Selective PI3Kδ Inhibition by GS-1101 Through Enhancing the Magnitude and Duration of p-AKT Inhibition

Mutation Burden in CDKN2C, CDK1 and E2F2 Is Associated with Differential Response to Targeting CDK4/CDK6 in Combination with Bortezomib in Mantle Cell Lymphoma,

Bim Is Required to Sensitize Mantle Cell Lymphoma Cells for Killing by Bortezomib, but Not Ara-C, by Selective Inhibition of CDK4/CDK6

A Phase I Study of PD 0332991: Complete CDK4/6 Inhibition and Tumor Response In Sequential Combination with Bortezomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma

MAGE-A Inhibits Apoptosis In Proliferating Multiple Myeloma Cells

A Phase I Trial of PD 0332991, a Novel, Orally-Bioavailable CDK4/6-Specific Inhibitor Administered in Combination with Bortezomib and Dexamethasone to Patients with Relapsed and Refractory Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only